Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093676236> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W3093676236 endingPage "S107" @default.
- W3093676236 startingPage "S106" @default.
- W3093676236 abstract "Cisplatin added to radiation therapy (RT) for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) is associated with a modest improvement in survival at the cost of increased toxicity, highlighting the need for newer agents. Immune checkpoint inhibitors (ICI) have a favorable safety profile and are the standard of care in recurrent/metastatic SCCHN, but their role in the definitive setting with RT remains to be determined. We conducted a single institution clinical trial assessing the safety of combined nivolumab (Nivo), a PD-1 inhibitor, and ipilimumab (Ipi), a CTLA-4 inhibitor, with concurrent RT in patients with high risk LA-SCCHN. Newly diagnosed, chemotherapy eligible patients (pts) with stage IVA-IVB p16(-) SCC of the oral cavity, oropharynx, larynx, and hypopharynx, or T4, N2c, or N3 p16(+) SCC of the oropharynx (AJCC 7th edition) were enrolled. Nivo (3 mg/kg Q2 weeks IV x17 doses) and Ipi (1 mg/kg Q6 weeks IV x6 doses) were administered 2 weeks prior to the start of RT. RT (70 Gy in 2 Gy daily fractions) was delivered to the primary tumor using VMAT and daily cone-beam CT IGRT. The primary objective was safety of combined ICI and RT. Between July 2017 and July 2019, 24 pts were enrolled with a median follow-up of 15 months (range 7-31); median age 60 (range 48-77); 20 male; 16 oropharynx (14 HPV+), 6 larynx, and 2 hypopharynx. All pts completed RT with no treatment delays. Seventeen out of twenty-four pts (71%) experienced grade 3 acute in-field adverse events (AE) consisting of mucositis (9), dysphagia (6), dermatitis (5), odynophagia (4), and dysphonia (1) during concurrent ICI-RT; there were no grade 4/5 AEs during ICI-RT. Five pts (22%) developed soft tissue ulcers (STU) at the primary tumor site during the ICI maintenance phase, one of which was not treated and led to a fatal carotid rupture. All STUs developed at a median of 91 (range 50-107) days post RT and were negative for viable tumor. Four primary site STUs were managed with either hyperbaric oxygen (HBO) (2), lingual artery embolization (1), or surgical debridement (1). One pt treated with HBO healed after 189 days while the pt who underwent debridement healed after 285 days. Two additional pts developed areas of necrosis at adjacent sites not involved by tumor, underwent surgical debridement, and healed after an average of 18.5 days. Two other pts experienced osteoradionecrosis (ORN) at sites of prior teeth extractions and were treated with HBO. Two pts experienced persistent inflammation without ulceration (PI). Six out of eleven pts (55%) with STU, necrosis, ORN, or PI discontinued maintenance ICI. Locoregional PFS is 100%. Combined PD-1 and CTLA-4 blockade with concurrent RT is associated with excellent locoregional control in high risk LA-SCCHN, albeit at the cost of in-field complications. Patients treated with such an approach should be closely monitored for soft tissue ulceration." @default.
- W3093676236 created "2020-10-29" @default.
- W3093676236 creator A5008924495 @default.
- W3093676236 creator A5009994644 @default.
- W3093676236 creator A5010670331 @default.
- W3093676236 creator A5015026678 @default.
- W3093676236 creator A5019641866 @default.
- W3093676236 creator A5041267516 @default.
- W3093676236 creator A5047513658 @default.
- W3093676236 creator A5057113388 @default.
- W3093676236 creator A5079427446 @default.
- W3093676236 creator A5085007713 @default.
- W3093676236 creator A5090187344 @default.
- W3093676236 date "2020-11-01" @default.
- W3093676236 modified "2023-10-02" @default.
- W3093676236 title "Nivolumab and Ipilimumab Combined with Definitive Radiation Therapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: In-field Toxicity Analysis of a Phase I Clinical Trial" @default.
- W3093676236 doi "https://doi.org/10.1016/j.ijrobp.2020.07.2289" @default.
- W3093676236 hasPublicationYear "2020" @default.
- W3093676236 type Work @default.
- W3093676236 sameAs 3093676236 @default.
- W3093676236 citedByCount "3" @default.
- W3093676236 countsByYear W30936762362021 @default.
- W3093676236 countsByYear W30936762362022 @default.
- W3093676236 crossrefType "journal-article" @default.
- W3093676236 hasAuthorship W3093676236A5008924495 @default.
- W3093676236 hasAuthorship W3093676236A5009994644 @default.
- W3093676236 hasAuthorship W3093676236A5010670331 @default.
- W3093676236 hasAuthorship W3093676236A5015026678 @default.
- W3093676236 hasAuthorship W3093676236A5019641866 @default.
- W3093676236 hasAuthorship W3093676236A5041267516 @default.
- W3093676236 hasAuthorship W3093676236A5047513658 @default.
- W3093676236 hasAuthorship W3093676236A5057113388 @default.
- W3093676236 hasAuthorship W3093676236A5079427446 @default.
- W3093676236 hasAuthorship W3093676236A5085007713 @default.
- W3093676236 hasAuthorship W3093676236A5090187344 @default.
- W3093676236 hasConcept C121608353 @default.
- W3093676236 hasConcept C126322002 @default.
- W3093676236 hasConcept C141071460 @default.
- W3093676236 hasConcept C143998085 @default.
- W3093676236 hasConcept C2775832928 @default.
- W3093676236 hasConcept C2776530083 @default.
- W3093676236 hasConcept C2776694085 @default.
- W3093676236 hasConcept C2777701055 @default.
- W3093676236 hasConcept C2780030458 @default.
- W3093676236 hasConcept C2780474809 @default.
- W3093676236 hasConcept C2781433595 @default.
- W3093676236 hasConcept C29730261 @default.
- W3093676236 hasConcept C31760486 @default.
- W3093676236 hasConcept C509974204 @default.
- W3093676236 hasConcept C71924100 @default.
- W3093676236 hasConceptScore W3093676236C121608353 @default.
- W3093676236 hasConceptScore W3093676236C126322002 @default.
- W3093676236 hasConceptScore W3093676236C141071460 @default.
- W3093676236 hasConceptScore W3093676236C143998085 @default.
- W3093676236 hasConceptScore W3093676236C2775832928 @default.
- W3093676236 hasConceptScore W3093676236C2776530083 @default.
- W3093676236 hasConceptScore W3093676236C2776694085 @default.
- W3093676236 hasConceptScore W3093676236C2777701055 @default.
- W3093676236 hasConceptScore W3093676236C2780030458 @default.
- W3093676236 hasConceptScore W3093676236C2780474809 @default.
- W3093676236 hasConceptScore W3093676236C2781433595 @default.
- W3093676236 hasConceptScore W3093676236C29730261 @default.
- W3093676236 hasConceptScore W3093676236C31760486 @default.
- W3093676236 hasConceptScore W3093676236C509974204 @default.
- W3093676236 hasConceptScore W3093676236C71924100 @default.
- W3093676236 hasIssue "3" @default.
- W3093676236 hasLocation W30936762361 @default.
- W3093676236 hasOpenAccess W3093676236 @default.
- W3093676236 hasPrimaryLocation W30936762361 @default.
- W3093676236 hasRelatedWork W2155654588 @default.
- W3093676236 hasRelatedWork W2323005616 @default.
- W3093676236 hasRelatedWork W2613324349 @default.
- W3093676236 hasRelatedWork W2891745547 @default.
- W3093676236 hasRelatedWork W2947988614 @default.
- W3093676236 hasRelatedWork W2970506413 @default.
- W3093676236 hasRelatedWork W4226292283 @default.
- W3093676236 hasRelatedWork W4308384320 @default.
- W3093676236 hasRelatedWork W4312069968 @default.
- W3093676236 hasRelatedWork W4318473990 @default.
- W3093676236 hasVolume "108" @default.
- W3093676236 isParatext "false" @default.
- W3093676236 isRetracted "false" @default.
- W3093676236 magId "3093676236" @default.
- W3093676236 workType "article" @default.